HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Nu Skin expansion

This article was originally published in The Rose Sheet

Executive Summary

Skin care direct-seller internally seeks to double its business to $2 bil. within five years with aggressive distribution strategy, which includes augmenting its presence in China, Provo, Utah company says during a Sept. 14 presentation at the Oppenheimer Business of Beauty Conference in New York City. Firm will move ahead with expansion in the region after China lifts ban on direct sales in December, Nu Skin notes. Currently operating fixed retail centers in 23 cities throughout the country, company also plans to launch retail stores, expand into 20 new cities over the next nine months and launch its dietary supplement division Pharmanex in China in 2005. Nu Skin debuted at retail in the country in early 2003 (1"The Rose Sheet" Oct. 14, 2002, p. 6)...

You may also be interested in...



Nu Skin China Debut Initially Targets 100 Retail Locations

Nu Skin Enterprises will launch marketing activities in China "in earnest" in January through roughly 100 retail outlets, President and CEO Steven Lund said at a Merrill Lynch analysts conference Oct. 1

US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising

US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”

Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa

The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.

Latest Headlines
See All
UsernamePublicRestriction

Register

RS012464

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel